Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arcturus Therapeutics Holdings Inc. (ARCT) is a Biotechnology company based in US with a market capitalization of $170.3M. Revenue declined 51.4% year-over-year and free cash flow was negative at -$74.5M. This page tracks ARCT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 174 employees · IPO May 22, 2013

Valuation

Valuation & price

$7.47as of May 17, 2026· -67.7% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.80

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$22.17$14.04$5.90Jul 25Jan 26Jul 26
$5.9052-week range$23.16
Loading valuation history…

Fundamentals

Key fundamentals

$170.3M

Market cap

-51.4%

Revenue growth (YoY)

95.5%

Gross margin

-$74.5M

Free cash flow (USD)

-$205.9M

Net debt

Net cash position

1.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$20.4M$67.2M

Free cash flow by year

20162025

-$19.3M-$74.5M

Gross margin by year

20212025

100.0%95.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 2, 2026Filing

    Strategic Collaboration

  • 8-K eventJun 5, 2026Filing

    Annual Meeting Results

  • 8-K eventMay 7, 2026Filing

    CFO Appointment

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is Arcturus Therapeutics Holdings Inc.'s market cap?

Arcturus Therapeutics Holdings Inc. (ARCT) has a market capitalization of $170.3M.

What is ARCT's P/E ratio?

A meaningful P/E ratio is not available for ARCT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARCT's price-to-book (P/B) ratio?

ARCT trades at 0.80 times book value per share.

Are insiders buying ARCT stock?

SEC Form 4 filings show no open-market insider buys at Arcturus Therapeutics Holdings Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.